DB:0E8

Stock Analysis Report

Advanced Proteome Therapeutics

Executive Summary

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States.

Rewards

Earnings have grown 18.6% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Does not have a meaningful market cap (€2M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months



Snowflake Analysis

Overvalued with weak fundamentals.

Share Price & News

How has Advanced Proteome Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0E8's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-85.0%

0

-8.1%

DE Biotechs

0.07%

DE Market


1 Year Return

-98.8%

0

5.9%

DE Biotechs

14.8%

DE Market

Return vs Industry: 0E8 underperformed the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: 0E8 underperformed the German Market which returned 17.1% over the past year.


Shareholder returns

0IndustryMarket
7 Day-85.0%-8.1%0.07%
30 Day-98.5%-3.4%1.4%
90 Day-97.0%12.2%6.1%
1 Year-98.8%-98.8%6.1%5.9%18.4%14.8%
3 Year-98.9%-98.9%56.9%55.1%17.4%7.0%
5 Year-99.8%-99.8%16.4%13.9%27.9%10.4%

Price Volatility Vs. Market

How volatile is Advanced Proteome Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Advanced Proteome Therapeutics undervalued compared to its fair value and its price relative to the market?

2.66x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 0E8's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 0E8's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 0E8 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 0E8 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 0E8's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 0E8 is good value based on its PB Ratio (2.7x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Advanced Proteome Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

38.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Advanced Proteome Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Advanced Proteome Therapeutics performed over the past 5 years?

18.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 0E8 is currently unprofitable.

Growing Profit Margin: 0E8 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 0E8 is unprofitable, but has reduced losses over the past 5 years at a rate of 18.6% per year.

Accelerating Growth: Unable to compare 0E8's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0E8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 0E8's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Advanced Proteome Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 0E8 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 0E8 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 0E8 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 0E8's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 0E8 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 0E8 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0E8 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 0E8 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -15.2% each year


Next Steps

Dividend

What is Advanced Proteome Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.5%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 0E8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 0E8's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0E8's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0E8's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0E8's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Advanced Proteome Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average board tenure


CEO

Paul Woodward (57yo)

0.4yrs

Tenure

0

Mr. Paul Woodward serves as President Chief Executive Officer & Director at Aether Catalyst Solutions, Inc. Mr. Woodward serves as the President & Director of Conation Capital Corp. Mr. Woodward was invest ...


Board Age and Tenure

1.0yrs

Average Tenure

57yo

Average Age

Experienced Board: 0E8's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buy€2,50223 Oct 19
Paul John Woodward
EntityIndividual
Role
Chief Executive Officer
President
Shares45,600
Max Price€0.055
Buy€6,62805 Jun 19
Paul John Woodward
EntityIndividual
Role
Chief Executive Officer
President
Shares100,000
Max Price€0.066
Buy€6,62805 Jun 19
Kenneth Phillippe
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares100,000
Max Price€0.066

Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Management Team

  • Ken Phillippe (66yo)

    Chief Financial Officer

    • Tenure: 10.2yrs
    • Compensation: US$17.04k
  • Paul Woodward (57yo)

    President

    • Tenure: 0.4yrs

Board Members

  • David Webb (72yo)

    Member of Corporate Advisory Board

    • Tenure: 4.2yrs
  • Ben Catalano (53yo)

    Director

    • Tenure: 0.4yrs
    • Compensation: US$6.78k
  • Martin John Woodward (50yo)

    Director

    • Tenure: 0.4yrs
  • Bill Dickie (62yo)

    Director

    • Tenure: 0.9yrs
    • Compensation: US$44.58k
  • Paul Wender

    Member of Scientific Advisory Board

    • Tenure: 1.3yrs
  • Paul Woodward (57yo)

    President

    • Tenure: 0.4yrs
  • Aditya Bardia

    Member of Scientific Advisory Board

    • Tenure: 1yrs
  • Greg Thurber

    Member of Scientific Advisory Board

    • Tenure: 1yrs
  • Benjamin Krantz

    Director

    • Tenure: 1.2yrs

Company Information

Advanced Proteome Therapeutics Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Advanced Proteome Therapeutics Corporation
  • Ticker: 0
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$2.254m
  • Listing Market Cap: CA$1.493m
  • Shares outstanding: 16.70m
  • Website: https://www.advancedproteome.com

Location

  • Advanced Proteome Therapeutics Corporation
  • BioSquare
  • 650 Albany Street
  • Boston
  • Massachusetts
  • 2118
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APTC.DOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 1989
APCTSXV (TSX Venture Exchange)YesCommon SharesCACADSep 1989
0DB (Deutsche Boerse AG)YesCommon SharesDEEURSep 1989
0MUN (Boerse Muenchen)YesCommon SharesDEEURSep 1989

Biography

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company. The company develops and commercializes a platform that is intended for the chemical modification of protein therapeutics, primarily antibody-drug conjugates. Its proprietary technology targets delivery of anti-cancer drugs to cancerous tumors. The company has collaboration agreements with Heidelberg Pharma AG and Noria Pharmaceuticals Inc.; and collaboration and option agreement with ImmunoBiochem Corporation. Advanced Proteome Therapeutics Corporation is headquartered in Boston, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/05/11 21:48
End of Day Share Price2019/05/07 00:00
Earnings2019/01/31
Annual Earnings2018/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.